Apalutamide
- Generic Name
- Apalutamide
- Brand Names
- Erleada
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15F4N5O2S
- CAS Number
- 956104-40-8
- Unique Ingredient Identifier
- 4T36H88UA7
- Background
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Ne...
- Indication
Apalutamide is indicated for the treatment of patients with metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- Androgen Deprivation Therapy
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 31
- Registration Number
- NCT04325828
- Locations
- ๐ฏ๐ต
National Cancer Center Hospital, Chuo Ku, Japan
๐ฏ๐ตNational Hospital Organization Kyushu Medical Center, Fukuoka, Japan
๐ฏ๐ตKansai Medical University Hospital, Hirakata City, Japan
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 7
- Registration Number
- NCT04267887
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy
- Conditions
- Interventions
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 490
- Registration Number
- NCT04181203
- Locations
- ๐ซ๐ท
Centre Antoine Lacassagne, Nice, France
๐ซ๐ทCentre Paul STRAUSS, Strasbourg, France
๐ซ๐ทCentre Georges Franรงois LECLERC, Dijon, France
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT04154774
- Locations
- ๐บ๐ธ
Homestead Associates in Research Inc, Homestead, Florida, United States
๐บ๐ธOrlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธGenesis Clinical Research, Tampa, Florida, United States
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
- Conditions
- Stage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage IIC Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIA Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IIB Prostate Cancer AJCC v8Prostate AdenocarcinomaStage IIIB Prostate Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 586
- Registration Number
- NCT04134260
- Locations
- ๐บ๐ธ
Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
๐บ๐ธMercy Cancer Center - Carmichael, Carmichael, California, United States
๐บ๐ธMercy San Juan Medical Center, Carmichael, California, United States
A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)
- Conditions
- Interventions
- First Posted Date
- 2019-09-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 75
- Registration Number
- NCT04108208
- Locations
- ๐จ๐ณ
Hunan Cancer hospital, Changsha, China
๐จ๐ณFujian Medical University Union Hospital, Fuzhou, China
๐จ๐ณZhejiang Cancer Hospital, Hang Zhou, China
A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naรฏve Prostate Cancer in Japan
- First Posted Date
- 2019-07-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 979
- Registration Number
- NCT04034095
- Locations
- ๐ฏ๐ต
Akita University Hospital, Akita, Japan
๐ฏ๐ตJuntendo University Hospital, Bunkyo Ku, Japan
๐ฏ๐ตTokyo Medical and Dental University Hospital, Bunkyo Ku, Japan
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT03902951
- Locations
- ๐บ๐ธ
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- Drug: Enzalutamide Oral CapsuleDrug: Niraparib plus Abiraterone acetate plus PrednisoneDrug: Capivasertib plus DocetaxelDrug: CarboplatinDrug: Abiraterone Oral TabletDrug: Cabazitaxel 60 mg Solution for InjectionDrug: ApalutamideDrug: DarolutamideDrug: Docetaxel Injectable SolutionDrug: Radium Chloride Ra-223
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 750
- Registration Number
- NCT03903835
- Locations
- ๐ง๐ช
University Hospital Ghent, Ghent, Belgium
๐ง๐ชOLV Ziekenhuis Aalst, Aalst, Belgium
๐ง๐ชAZ Groeninge, Kortrijk, Belgium
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cancer Research Antwerp
- Target Recruit Count
- 202
- Registration Number
- NCT03899077
- Locations
- ๐ง๐ช
AZ Sint-Jan, Brugge, Belgium
๐ง๐ชOLVZ Aalst, Aalst, Belgium
๐ง๐ชCH Jolimont, Haine-Saint-Paul, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.